Kazia Therapeutics (NASDAQ: KZIA)

Last close As at 09/12/2025

0.00 (0.00%)

Market capitalisation

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Latest Insights

View More

Thematics

thematic

Investment Companies

Edison explains: AI slop – when fake news costs real money

thematic

Financials

Digital assets – Part 4: Asset tokenisation and payments